At-Home Light-Emitting Diode Devices Safe, Effective for Acne Treatment
By Lori Solomon HealthDay Reporter
THURSDAY, March 6, 2025 -- At-home light-emitting diode (LED) devices are effective for treating acne, according to a research letter published online March 5 in JAMA Dermatology.
Sherry Ershadi and John S. Barbieri, M.D., from Brigham and Women’s Hospital in Boston, conducted a systematic review and meta-analysis to synthesize the available data regarding the safety and efficacy of at-home LED devices in the treatment of mild-to-moderate acne.
Based on data from six studies (216 participants; age range, 12 to 50 years), the researchers found that compared with control, the LED devices resulted in greater percent change in inflammatory lesions (45.3 percent; I2 = 43.2 percent; five studies), noninflammatory lesions (47.7 percent; I2 = 83.22 percent; four studies), and the Investigator Global Assessment (45.7 percent; I2 = 54.85 percent; four studies). Red, blue, and combination wavelength devices were all effective. Benefit was typically seen after four to 12 weeks of use. There were no severe adverse reactions reported; however, a small number of patients did report mild dryness, erythema, or discomfort or pain during light therapy.
"At-home LED devices, particularly those that combine red and blue light, are efficacious for acne and can likely complement other over-the-counter and prescription treatments," the authors write.
Barbieri disclosed ties to Honeydew Care, Dexcel Pharma, and Sanofi Pasteur.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-03-07 06:00
Read more

- FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva
- Cancer Rates Are Falling in Appalachia, But Not Enough
- Second Death From Measles Reported in Unvaccinated Adult in New Mexico
- Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
- Boarding Common While Awaiting Acute Pediatric Psychiatric Care
- AI Contributes to Early Detection of Clinically Relevant Breast Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions